TLRY Tilray Brands, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1731348 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.9%
TTM net income YoY92.4%
TTM EPS YoY94.2%
Revenue 3-yr CAGR14.0%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-9.3%
Net margin-17.1%
FCF margin—
EBITDA margin—
Returns
ROE-10.4%
ROA-7.4%
ROIC (approx.)-5.0%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.08x
Current ratio1.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.51x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 | FY20222022-05-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $915.45M | $821.31M | $788.94M | $627.12M | $628.37M |
| Cost of revenue | $655.01M | $580.74M | $565.59M | $480.16M | $511.56M |
| Gross profit | $260.44M | $240.57M | $223.35M | $146.96M | $116.82M |
| R&D expense | $361,000 | $284,000 | $635,000 | $682,000 | $1.52M |
| SG&A expense | $203.63M | $167.32M | $167.36M | $165.16M | $162.80M |
| Operating income | -$63.03M | -$2.28B | -$174.75M | -$1.37B | -$610.40M |
| Interest expense | $29.91M | $41.33M | $49.26M | $46.61M | $39.68M |
| Pretax income | -$88.06M | -$2.30B | -$249.02M | -$1.45B | -$440.67M |
| Income tax | $17.10M | -$121.02M | -$26.62M | -$7.18M | -$6.54M |
| Net income | -$121.40M | -$2.19B | -$244.98M | -$1.45B | -$476.80M |
| EBITDA | — | — | — | — | -$455.81M |
| EPS (basic) | -1.09 | -24.56 | -3.30 | -2.35 | -0.99 |
| EPS (diluted) | -1.09 | -24.56 | -3.30 | -2.35 | -0.99 |
| Weighted avg. shares (diluted) | 111.83M | 89.03M | 74.26M | 617.98M | 481.22M |
| Balance sheet | |||||
| Cash & equivalents | $225.98M | $221.67M | $228.34M | $206.63M | $415.91M |
| Short-term investments | $5.29M | $34.70M | $32.18M | $241.90M | $0 |
| Receivables | $189.17M | $121.49M | $101.69M | $86.23M | $95.28M |
| Inventory | $301.19M | $270.88M | $252.09M | $200.55M | $245.53M |
| Current assets | $792.13M | $688.63M | $677.71M | $773.03M | $803.50M |
| PP&E, net | $680.23M | $568.43M | $558.25M | $429.67M | $587.50M |
| Goodwill | $752.35M | $752.35M | $2.01B | $2.01B | $2.64B |
| Intangibles | $42.78M | $21.42M | $915.47M | $973.78M | $1.28B |
| Total assets | $2.33B | $2.07B | $4.22B | $4.31B | $5.45B |
| Current liabilities | $358.38M | $280.30M | $299.17M | $432.98M | $280.34M |
| Short-term debt | $8.78M | $7.18M | $18.03M | $23.38M | $18.12M |
| Long-term debt | $120.42M | — | — | — | $117.88M |
| Total debt | $129.20M | — | — | — | $136.00M |
| Total liabilities | $733.14M | $584.75M | $778.49M | $977.32M | $1.01B |
| Shareholders' equity | $1.61B | $1.51B | $3.44B | $3.32B | $4.40B |
| Net debt | -$96.78M | — | — | — | -$279.91M |
| Shares outstanding | 131.68M | 106.07M | 831.93M | 656.66M | 532.67M |
| Cash flow statement | |||||
| Operating cash flow | -$69.14M | -$94.60M | -$30.91M | $7.91M | -$177.26M |
| Capital expenditure | — | $32.92M | $29.25M | $20.80M | $34.06M |
| Free cash flow | — | -$127.52M | -$60.15M | -$12.89M | -$211.33M |
| Investing cash flow | -$55.80M | -$46.72M | $128.35M | -$285.11M | -$21.53M |
| Financing cash flow | $130.99M | $133.51M | -$75.19M | $70.16M | $128.20M |
| Depreciation & amortization | — | — | — | — | $154.59M |
| Stock-based compensation | $45.94M | $24.29M | $31.77M | $39.59M | $35.99M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.